Unveiling the enzymatic activity of a dimeric LDH isoform and its implications for allosteric inhibition strategies
Protein Science · 2025
DOI: 10.1002/pro.70367 ↗At a glance
Journal article in Protein Science, 2025. Written by Ferran Nadal-Bufi and 10 co-authors. Institution: Medicinal Chemistry Research Group (CMFA), Louvain Drug Research Institute (LDRI), Université catholique de Louvain (UCLouvain), Brussels, Belgium. Major MEDLINE topics: L-Lactate Dehydrogenase, Protein Multimerization, Enzyme Inhibitors. Cited 2 times so far (Crossref); 39 references. The full text is freely available in PubMed Central. Funded by: French Community of Belgium, Belgian Fonds National de la Recherche Scientifique, Belgian Fondation contre le Cancer.
Abstract (original language)
Lactate dehydrogenase (LDH) is a key enzyme in cancer metabolism, with isoforms LDH5 and LDH1 supporting glycolysis and oxidative lactate metabolism, respectively. While the development of competitive LDH inhibitors has faced diverse challenges, allosteric strategies targeting LDH tetramerization have recently attracted increasing attention. To further explore this alternative, we investigated the factors influencing LDH tetramerization and enzymatic activity using a truncated form of human LDH‐B (LDHBtr), which was reported to exist predominantly as a dimer. Unexpectedly, LDHBtr exhibited measurable activity at high concentrations, correlating with increased protein stability and a structural transition to the tetrameric form. Preincubation with NADH further enhanced LDHBtr activity, stability, and self‐association, consistent with cofactor‐promoted tetramer assembly. Crystallographic studies confirmed the tetrameric structure of LDHBtr bound to NADH. Furthermore, reported LDH allosteric inhibitors, including cGmC9 and fluoxetine, preferentially inhibited LDHBtr compared to the native LDHB, by preventing tetramer formation. Overall, this work highlights the central role of tetramerization in regulating LDH activity, and the therapeutic potential of targeting this process. It also establishes LDHBtr as a valuable tool for screening tetramerization disruptors, paving the way for next‐generation LDH inhibitors to target cancer metabolism.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Medicinal Chemistry Research Group (CMFA), Louvain Drug Research Institute (LDRI), Université catholique de Louvain (UCLouvain), Brussels, Belgium.
- Namur Institute of Structured Matter and Namur Research Institute for Life Sciences, Department of Chemistry, University of Namur, Namur, Belgium.
- Pole of Pharmacology and Therapeutics, Institut de Recherche Expérimentale et Clinique (IREC), Université catholique de Louvain (UCLouvain), Brussels, Belgium.
- WEL Research Institute, WELBIO Department, Wavre, Belgium.
- Laboratory for the Analysis of Medicines (CIRM), University of Liege (ULiege), Liège, Belgium.
ORCID profiles: Ferran Nadal-Bufi, Raphaël Frédérick
Funding
- French Community of Belgium
- Belgian Fonds National de la Recherche Scientifique
- Belgian Fondation contre le Cancer
- Télévie
- Fédération Wallonie-Bruxelles
Cite
APA
Nadal-Bufi, F., Van Gysel, M., Brustenga, C., Savoyen, P., Mathieu, C., Gobert, A., Sonveaux, P., Spillier, Q., Fillet, M., Wouters, J., & Frédérick, R. (2025). Unveiling the enzymatic activity of a dimeric LDH isoform and its implications for allosteric inhibition strategies. Protein Science. https://doi.org/10.1002/pro.70367
Vancouver
Nadal-Bufi F, Van Gysel M, Brustenga C, Savoyen P, Mathieu C, Gobert A, et al. Unveiling the enzymatic activity of a dimeric LDH isoform and its implications for allosteric inhibition strategies. Protein Science. 2025. doi:10.1002/pro.70367
BibTeX
@article{NadalBufi2025,
author = {Nadal-Bufi, Ferran and Van Gysel, Mégane and Brustenga, Chiara and Savoyen, Perrine and Mathieu, Caroline and Gobert, Alexandre and Sonveaux, Pierre and Spillier, Quentin and Fillet, Marianne and Wouters, Johan and Frédérick, Raphaël},
title = {Unveiling the enzymatic activity of a dimeric LDH isoform and its implications for allosteric inhibition strategies},
journal = {Protein Science},
year = {2025},
doi = {10.1002/pro.70367}
}
EUVIMED